RecruitingNot ApplicableNCT02633553
Adjuvant Radiotherapy for Stage II/III Thymoma After Complete Resection
An Open-label, Multi-center, Randomized Phase III Study of Adjuvant Radiotherapy for Stage II/III Thymoma After Complete Resection
Sponsor
Fudan University
Enrollment
238 participants
Start Date
Jan 10, 2018
Study Type
INTERVENTIONAL
Conditions
Summary
This study is designed to investigate whether adjuvant radiotherapy after complete resection has a better survival for stage II or III thymoma.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria1
- ~75 years old; Eastern Cooperative Oncology Group performance status of 0 to 2; Pathologically confirmed masaoka stage II or III thymoma; Have adequate bone marrow, hepatic, and renal function; Patients receive complete resection within 3 months; Written informed consent.
Exclusion Criteria1
- Patients with distant metastases; Patients underwent radiotherapy or chemotherapy; Patients who have malignancy history excluding carcinoma in situ of cervix in the previous five years; Active clinical pulmonary infection; Pregnant or nursing.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
RADIATIONadjuvant radiotherapy
50Gy/25Fx
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02633553
Related Trials
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
NCT019505721 location
A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors
NCT062485154 locations
Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma
NCT068389101 location
Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma
NCT067303081 location
Hypofractionated Radiotherapy for Thymic Epithelial Tumors
NCT066920621 location